Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 7/20 | 0.41 |
| ▸ | PLD2 | O14939 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | STAMBP | O95630 | 1/20 | 0.40 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CALCA | P06881 | 1/20 | 0.37 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52562 | 0.89 | KCNH2 (0.45) | KCNH2CYP2C9SMN1; SMN2CALCAERCC1 | |
| SCHEMBL52473 | 0.86 | KCNH2 (0.43) | KCNH2CYP2C9HDAC3HDAC1HDAC2 | |
| SCHEMBL64514 | 0.86 | KCNH2 (0.42) | KCNH2CYP2C9NAMPTCALCAERCC1 | |
| SCHEMBL64481 | 0.85 | KCNH2 (0.45) | KCNH2CYP2C9SMN1; SMN2CALCAERCC1 | |
| SCHEMBL52520 | 0.85 | L3MBTL1 (0.47) | KCNH2CYP2C9NAMPTSMN1; SMN2CALCA | |
| SCHEMBL64238 | 0.85 | KCNH2 (0.44) | KCNH2CYP2C9SMN1; SMN2CALCAERCC1 | |
| SCHEMBL53206 | 0.85 | KCNH2 (0.43) | KCNH2CYP2C9SMN1; SMN2CALCAERCC1 | |
| SCHEMBL418372 | 0.84 | KCNH2 (0.47) | KCNH2CYP2C9SMN1; SMN2CALCAERCC1 | |
| SCHEMBL63410 | 0.84 | SMN1; SMN2 (0.53) | KCNH2CYP2C9SMN1; SMN2ERCC1FEN1 | |
| SCHEMBL52470 | 0.83 | KCNH2 (0.49) | KCNH2CYP2C9SMN1; SMN2CALCAERCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | PLD1 4235/4885PLD2 4630/4885KCNH2 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.